NIAID Banner Logo Image

Other Viruses Citation List: March 13 - March 26, 2015

Hepatitis A Virus

1. The JAK2 Inhibitor AZD1480 Inhibits Hepatitis A Virus Replication in Huh7 Cells. Jiang, X., T. Kanda, S. Nakamoto, K. Saito, M. Nakamura, S. Wu, Y. Haga, R. Sasaki, N. Sakamoto, H. Shirasawa, H. Okamoto, and O. Yokosuka. Biochemical and Biophysical Research Communications, 2015. 458(4): p. 908-912. PMID[25704089].

[PubMed]. OV_0313-032615.

Hepatitis C Virus

2. Synthesis of bis-Macrocyclic HCV Protease Inhibitor MK-6325 via Intramolecular sp(2)-sp(3) Suzuki-Miyaura Coupling and Ring Closing Metathesis. Li, H., J.P. Scott, C.Y. Chen, M. Journet, K. Belyk, J. Balsells, B. Kosjek, C.A. Baxter, G.W. Stewart, C. Wise, M. Alam, Z.J. Song, and L. Tan. Organic Letters, 2015. 17(6): p. 1533-1536. PMID[25754231].

[PubMed]. OV_0313-032615.

Feline Immunodeficiency Virus

3. Novel Fused Tetrathiocines as Antivirals That Target the Nucleocapsid Zinc Finger Containing Protein of the Feline Immunodeficiency Virus (FIV) as a Model of HIV Infection. Asquith, C.R., M.L. Meli, L.S. Konstantinova, T. Laitinen, A. Poso, O.A. Rakitin, R. Hofmann-Lehmann, K. Allenspach, and S.T. Hilton. Bioorganic & Medicinal Chemistry Letters, 2015. 25(6): p. 1352-1355. PMID[25702849].

[PubMed]. OV_0313-032615.

Human Cytomegalovirus

4. Polyoxygenated Cembrane Diterpenoids from the Soft Coral Sarcophyton ehrenbergi. Cheng, S.Y., S.K. Wang, M.K. Hsieh, and C.Y. Duh. International Journal of Molecular Sciences, 2015. 16(3): p. 6140-6152. PMID[25789502].

[PubMed]. OV_0313-032615.

Herpes Simplex Virus 1

5. Synergistic Effects of Acyclovir and 3, 19-Isopropylideneandrographolide on Herpes Simplex Virus Wild Types and Drug-resistant Strains. Priengprom, T., T. Ekalaksananan, B. Kongyingyoes, S. Suebsasana, C. Aromdee, and C. Pientong. BMC Complementary and Alternative Medicine, 2015. 15(56): 8pp. PMID[25783941].

[PubMed]. OV_0313-032615.

Citations from the ISI Web of Knowledge Listings for O.V.

6. Drug-drug Interactions of Carbamazepine with the HCV Direct Acting Antiviral (DAA) Combination of ABT-450/R, Ombitasvir and Dasabuvir. Badri, P., S. Dutta, A. Asatryan, H. Wang, I. Podsadecki, W. Awni, and R. Menon. Clinical Pharmacology & Therapeutics, 2015. 97: p. S23-S24. ISI[000348730500064].

[WOS]. OV_0313-032615.


7. Drug-drug Interactions of Digoxin with the HCV Direct Acting Antiviral (DAA) Combination of ABT-450/R, Ombitasvir and Dasabuvir. Badri, P., S. Dutta, L. Rodrigues, B. Ding, T. Podsadecki, W. Awni, and R. Menon. Clinical Pharmacology & Therapeutics, 2015. 97: p. S25-S25. ISI[000348730500068].

[WOS]. OV_0313-032615.


8. Potent Hepatitis C Virus NS5A Inhibitors; Discovery of BMK-20113. Bae, I.H. and B.M. Kim. Abstracts of Papers of the American Chemical Society, 2014. 248: Poster #613. ISI[000349167403198].

[WOS]. OV_0313-032615.


9. Novel Naphthalene Derivatives as Potent HCV NS5A Inhibitors: Design, Synthesis, SAR, and Optimization Studies. Baskaran, S., W. Kazmierski, M.S. Duan, S. Dickerson, J. Cooper, R. Grimes, and J. Walker. Abstracts of Papers of the American Chemical Society, 2014. 248: Poster #407. ISI[000349167402206].

[WOS]. OV_0313-032615.


10. ProTides of N-(3-(5-(2 '-Deoxyuridine))prop-2-ynyl)octanamide Phosphate, a Potent and Selective Inhibitor of Thymidylate Synthase X from Mycobacterium Tuberculosis, as Potential Anti-tubercular and Anti-viral Agents. Ferrari, V., C. McGuigan, M. Derudas, B. Gonczy, K. Hinsinger, S. Kandil, F. Pertusati, M. Serpi, R. Snoeck, G. Andrei, J. Balzarini, T.D. McHugh, A. Maitra, E. Akorli, D. Evangelopoulos, and S. Bhakta. Abstracts of Papers of the American Chemical Society, 2014. 248: Poster #392. ISI[000349167402192].

[WOS]. OV_0313-032615.


11. Discovery of Inhibitors of the Hepatitis C Virus Using a Cell-based Infection Assay. He, S.S., K.L. Li, Z.Y. Hu, M. Ferrer, N. Southall, B. Lin, J.B. Xiao, X. Hu, W. Zheng, J.J. Marugan, J. Aube, F.J. Schoenen, K.J. Frankowski, and T.J. Liang. Abstracts of Papers of the American Chemical Society, 2014. 248: Poster #13. ISI[000349167401719].

[WOS]. OV_0313-032615.


12. HCV NS5A Replication Complex Inhibitors: Effects of Substituted Pyrrolidines in Balancing Genotype 1a/1b Potency. Henderson, J.A., B.C. Liu, S. Giroux, T.J. Reddy, M. Bubenik, C. Cadilhac, L. Vaillancourt, G. Falardeau, C. Poisson, O. Pereira, K.M. Cottrell, M. Morris, O. Nicolas, D. Bilimoria, N. Mani, N. Ewing, R. Shawgo, L. L'Heureux, S. Selliah, A.L. Grillot, Y.L. Bennani, and J.P. Maxwell. Abstracts of Papers of the American Chemical Society, 2014. 248: Poster #421. ISI[000349167402219].

[WOS]. OV_0313-032615.


13. Discovery of a Novel Lactam-containing Non-nucleoside Class of HCV NS5B Inhibitors. Li, P., J. Green, D. Lauffer, Q. Tang, L. Chan, C. Poisson, J. Court, N. Waal, S. Ronkin, S. Nanthakumar, S.K. Das, C. Yannopoulos, W. Dorsch, N. Mani, D. Bilimoria, R. Shawgo, G. Rao, O. Nicolas, N. Chauret, S. Selliah, and F. Denis. Abstracts of Papers of the American Chemical Society, 2014. 248: Poster #81. ISI[000349167401784].

[WOS]. OV_0313-032615.


14. Antiviral Drug Discovery and Development: Progress of the HCV Inhibitors Asunaprevir and BMS-791325 and the HIV-1 Attachment Inhibitor BMS-663068. Meanwell, N.A. Abstracts of Papers of the American Chemical Society, 2014. 247: Poster #224. ISI[000348457602389].

[WOS]. OV_0313-032615.


15. Pharmacokinetic Interaction of HCV NS3/4A Protease Inhibitor Vaniprevir and Rosuvastatin. Orito, Y., T. Iwasa, N. Uemura, G. Fujimoto, S. Yama, W. Gao, L. Caro, C. Fandozzi, T. Prucksaritanont, M. Anderson, J. Butterton, and S. Hasegawa. Clinical Pharmacology & Therapeutics, 2015. 97: p. S24-S25. ISI[000348730500066].

[WOS]. OV_0313-032615.


16. Drug-drug Interactions of Omeprazole with the HCV Direct Acting Antiviral (DAA) Combination of ABT-450/R, Ombitasvir and Dasabuvir. Polepally, A.R., S. Dutta, T. Baykal, B. Hu, T.J. Podsadecki, W.M. Awni, and R.M. Menon. Clinical Pharmacology & Therapeutics, 2015. 97: p. S77-S78. ISI[000348730500240].

[WOS]. OV_0313-032615.


17. Discovery of Novel Catalytic Technologies in the Process Development of HCV Polymerase Inhibitors. Shekhar, S. Abstracts of Papers of the American Chemical Society, 2014. 248: Poster #9. ISI[000349167402478].

[WOS]. OV_0313-032615.


18. 17Beta-Estradiol Inhibits Hepatitis C (HCV) Infection via Binding to its Receptor. Giarda, P., A. Magri, C.Z. Foglia, E. Boccato, E.M. Burlone, R. Minisini, E. Grossini, and M. Pirisi. Digestive and Liver Disease, 2015. 47: p. E14-E15. ISI[000349979500029].

[WOS]. OV_0313-032615.


19. Feleucin-BO1: A Novel Antimicrobial Non-apeptide amide from the Skin Secretion of the Toad, Bombina orientalis, and Design of a Potent Broad-spectrum Synthetic Analogue, Feleucin-K3. Hou, X.J., Q. Du, R.J. Li, M. Zhou, H. Wang, L. Wang, C. Guo, T.B. Chen, and C. Shaw. Chemical Biology & Drug Design, 2015. 85(3): p. 259-267. ISI[000350112600003].

[WOS]. OV_0313-032615.


20. Anti-Hepatitis B Virus Active Constituents from Swertia chirayita. Zhou, N.J., C.A. Geng, X.Y. Huang, Y.B. Ma, X.M. Zhang, J.L. Wang, and J.J. Chen. Fitoterapia, 2015. 100: p. 27-34. ISI[000349881300005].

[WOS]. OV_0313-032615.

Special Search Request Citations

21. Pharmacokinetic and Pharmacodynamic Properties of GS-9620, a Novel Toll-Like Receptor 7 Agonist, Demonstrate Interferon-stimulated Gene Induction without Detectable Serum Interferon at Low Oral Doses. Fosdick, A., J. Zheng, S. Pflanz, C.R. Frey, J. Hesselgesser, R.L. Halcomb, G. Wolfgang, and D.B. Tumas. The Journal of Pharmacology and Experimental Therapeutics, 2014. 348(1): p. 96-105. PMID[24133297].

[Special Search]. OV_0313-032615.


22. Identification and Optimization of Pteridinone Toll-Like Receptor 7 (TLR7) Agonists for the Oral Treatment of Viral Hepatitis. Roethle, P.A., R.M. McFadden, H. Yang, P. Hrvatin, H. Hui, M. Graupe, B. Gallagher, J. Chao, J. Hesselgesser, P. Duatschek, J. Zheng, B. Lu, D.B. Tumas, J. Perry, and R.L. Halcomb. Journal of Medicinal Chemistry, 2013. 56(18): p. 7324-7333. PMID[23961878].

[Special Search]. OV_0313-032615.


23. Pharmaceutical Combinations Comprising a Thionucleotide Analog and other Agents for Treating a Hepatitis C Virus Infection. Blatt, L.M., L. Beigelman, H. Tan, J.A. Symons, D.B. Smith, M. Jiang, T.L. Kieffer, and C.A. Rijnbrand. Patent. 2013. 2013-US30594 2013142157: 406pp.

[Special Search]. OV_0313-032615.


24. Preparation of Pyridazinylmethylimidazopyridine Derivatives and Analogs for Use in the Treatment of Hepatitis C Virus using Combination Chemotherapy. Delaney, W.E., J.O. Link, H. Mo, D.W. Oldach, A.S. Ray, W.J. Watkins, C.Y. Yang, and W. Zhong. Patent. 2012. 2011-US64017 2012087596: 143pp.

[Special Search]. OV_0313-032615.


25. Preparation of Fatty acid Antiviral Conjugates. Milne, J.C., M.R. Jirousek, C.B. Vu, A. Wensley, and A. Ting. Patent. 2013. 2012-US69229 2013090420: 264pp.

[Special Search]. OV_0313-032615.


26. Preparation of Pyridazinylmethylimidazopyridine Derivatives and Analogs for Use in the Treatment of Hepatitis C Virus Using Combination Chemotherapy. Ray, A.S., W.J. Watkins, J.O. Link, D.W. Oldach, and W.E.I.V. Delaney. Patent. 2013. 2012-US55621 2013040492: 159pp.

[Special Search]. OV_0313-032615.


27. Preparation of Substituted Nucleosides, Nucleotides and Analogs thereof as Protease and Polymerase Inhibitors for Treatment of HCV Infection. Smith, D.B., L. Beigelman, G. Wang, and M.H. Welch. Patent. 2014. 2013-US76727 2014100498: 148pp.

[Special Search]. OV_0313-032615.


28. Preparation of Substituted Phosphorothioate Nucleotide Analogs as Antiviral Agents. Wang, G. and L. Beigelman. Patent. 2013. 2012-US71064 2013096680: 167 pp.

[Special Search]. OV_0313-032615.


29. Determinants of Activity at Human Toll-like Receptors 7 and 8: Quantitative Structure-Activity Relationship (QSAR) of Diverse Heterocyclic Scaffolds. Yoo, E., D.B. Salunke, D. Sil, X. Guo, A.C. Salyer, A.R. Hermanson, M. Kumar, S.S. Malladi, R. Balakrishna, W.H. Thompson, H. Tanji, U. Ohto, T. Shimizu, and S.A. David. Journal of Medicinal Chemistry, 2014. 57(19): p. 7955-7970. PMID[25192394].

[Special Search]. OV_0313-032615.

If using ChemDB information for publication or abstract presentation, please cite the website in addition to the original information source.    Database last updated: September 2024